Medullary thyroid cancer diagnosis: An appraisal
Transcript of Medullary thyroid cancer diagnosis: An appraisal
Medullary Thyroid Cancer Diagnosis: An Appraisal
Pierpaolo Trimboli 1, Luca Giovanella 2, Anna Crescenzi 3,4, Francesco Romanelli 5,
Stefano Valabrega 6, Giuseppe Spriano 7, Nadia Cremonini 8, Rinaldo Guglielmi 9, Enrico
Papini 9
1 Section of Endocrinology and Diabetology, Ospedale Israelitico, Rome, Italy.
2 Department of Nuclear Medicine and Thyroid Centre, Oncology Institute of Southern
Switzerland, Bellinzona, Switzerland.
3 Section of Pathology, Ospedale Israelitico, Rome, Italy.
4 Anatomic Pathology Unit, Ospedale Regina Apostolorum, Albano Laziale, Rome, Italy.
5 Department of Experimental Medicine, Sapienza University, Rome, Italy.
6 Department of Medical and Surgical Sciences, Ospedale S. Andrea, Sapienza University,
Rome, Italy.
7 Department of Otolaryngology, Head & Neck Surgery, Istituto Nazionale Tumori Regina
Elena, Rome, Italy.
8 Endocrinology Unit, Ospedale Maggiore, Bologna, Italy.
9 Department of Endocrinology, Ospedale Regina Apostolorum, Albano Laziale, Rome,
Italy.
Corresponding author:
Dr. Enrico Papini
Department of Endocrinology, Ospedale Regina Apostolorum,
Via San Francesco 50, 00041 – Albano (Rome), Italy
Tel: + 39 333 6235608
e-mail: [email protected]
Running title: diagnosing medullary thyroid cancer.
Key words: thyroid; carcinoma; calcitonin; cytology; RET.
Disclosure statement: the authors have nothing to disclose.
Head & Neck
This article has been accepted for publication and undergone full peer review but has not beenthrough the copyediting, typesetting, pagination and proofreading process which may lead todifferences between this version and the Version of Record. Please cite this article as an‘Accepted Article’, doi: 10.1002/hed.23449
2
Abstract
Since its first description in 1951, a timely diagnosis of medullary thyroid
cancer (MTC) may represent a diagnostic challenge in clinical practice. Several
contributes have been addressed to the treatment and follow-up of MTC, but review
papers focused on the diagnostic problems of this cancer in clinical practice are
sparse. As a delayed diagnosis and an inadequate initial treatment may severely
affect the prognosis of this thyroid malignancy, the appropriate use and the correct
interpretation of the available diagnostic tools for MTC is of crucial importance. The
present paper is aimed to provide an easy-to-use guide reviewing the main issues of
MTC diagnosis:
1. Basal serum Calcitonin (CT)
2. Stimulated serum CT
3. Additional serum markers for MTC
4. Ultrasonography and other imaging techniques
5. Fine needle aspiration cytology (FNA)
6. CT measurement on FNA washout (FNA-CT)
7. RET (REarranged during Transfection) mutations
Scope of the problem
MTC is a malignant tumor originating from thyroid parafollicular C cells and
accounts for less than 5% of thyroid cancers (1,2). MTC is part of an autosomal dominant
inherited disorder (MEN 2 A and B and familial MTC) in about 20% of cases and presents
as sporadic tumor in the remainder (2,3). The identification of MTC as a neuroendocrine
tumor producing CT and the use of CT as an immunohistochemical marker improved the
histologic assessment of MTC and has resulted in an increased incidence of this
malignancy (4).
Since its first description in 1951 (5), the diagnosis of MTC may represent a
diagnostic challenge in clinical practice. Fine needle aspiration biopsy (FNA) of thyroid
nodules, currently the most accurate tool for detecting thyroid malignancies, reveals a
diagnostic accuracy for this cancer type less consistent than for differentiated thyroid
carcinoma (6,7). The sensitivity for MTC of serum calcitonin (CT) has been reported as
higher than ultrasound (US) examination and cytology but the actual diagnostic accuracy
of this marker and its use as a routine test in clinical practice are still a matter of debate
Page 2 of 26
John Wiley & Sons, Inc.
Head & Neck
3
(1,8,9). Currently, histologic identification of MTC is quite reliable, but the issues of its early
clinical detection and pre-operatory confirmation remain in part unsettled. Due to these
persistent diagnostic gray zones, a part of MTC is still incidentally discovered after thyroid
surgery with the risk of an incomplete therapeutic approach and of a less favourable
prognosis (10). A tailored surgical approach, including total thyroidectomy, central neck
nodal and, in a few cases, lateral neck nodal dissection, is needed for an appropriate
treatment (2) but requires an early pre-surgical diagnosis and a correct clinical staging of
MTC.
Several original contributes, review articles and consensus documents (2,11) have
been addressed to the treatment and follow-up of MTC but reviews focused on the
diagnostic problems of this cancer in clinical care are sparse. As a delayed diagnosis and
an inadequate initial treatment severely affect the prognosis of this thyroid malignancy, the
present paper will be aimed to the following aspects of MTC diagnosis:
1. Basal serum Calcitonin (CT)
2. Stimulated serum CT
3. Additional serum markers for MTC
4. Ultrasonography and other imaging techniques
5. Fine needle aspiration cytology (FNA)
6. CT measurement on FNA washout (FNA-CT)
7. RET (REarranged during Transfection) mutations
Methods
Articles were obtained by searching in PubMed MEDLINE the following search
MeSH: medullary carcinoma OR medullary thyroid cancer OR medullary thyroid carcinoma
OR RET OR calcitonin. The limits of the search included ‘‘humans’’, ‘‘randomized
controller trials’’ or ‘‘meta-analysis’’. Also, UpToDate (www.uptodate.com) was browsed. In
addition to these articles, numerous additional relevant articles, book chapters, and other
materials were also supplied by the authors.
Diagnostic issues
1. Basal serum Calcitonin (CT)
1.1 Which methods are available for the determination of serum CT?
Page 3 of 26
John Wiley & Sons, Inc.
Head & Neck
4
Serum CT determination has evolved over time, with methods changing from
competitive radioimmunoassays (RIAs) to ‘sandwich’ immunoradiometric assays (IRMAs)
(12). Due to the variable level of the different products of the CT gene, RIA determinations
tend to be (up to 10 times) higher than those of sandwich IRMA analytical methods (13).
Recently, immunoassays that incorporate non-radioisotopic enzymatic (IEMA) or
luminescent (ICMA) methods have become available on fully-automated platforms. Hence,
most laboratories have moved routine CT measurement from manual IRMA methods (14,
15) to automated assay platforms with comparable analytical performances (16).
Due to the poor inter-method and inter-laboratory agreement, reflecting differences
in calibration and specificity of antibodies (17), the laboratory report of serum CT
measurement should specify the type of CT assay, its characteristics and its reference
limits (2).
1.2 How to obtain and handle blood samples for CT measurement?
The blood sample should be drawn from a fasting patient. Due to the low stability of
serum CT at room temperature, it is necessary to centrifuge the sample immediately after
blood coagulation and to freeze and transport it in ice to the laboratory.
1.3 Which are the limits of serum CT in normal population?
Healthy subjects almost always have a serum CT concentration <10 pg/mL on
IRMA determination (18). This threshold level was adopted in several clinical guidelines
and is widely used in clinical practice (19). The upper reference limit for males, however,
should be set at a higher level than for females. The use of gender-specific CT reference
ranges (20-23) is supported by autoptic studies which demonstrate that the number of C
cells is approximately two times higher in men than in women and by the evidence of a
positive relationship between serum CT and thyroid volume (that is higher in males than in
females). To establish normal limits of CT in healthy subjects is difficult due to the
significant variability in diagnostic accuracy and reference ranges of the different
commercially available assays (23).
Each laboratory should assess its own normal references by using data derived
from local control series. As an alternative option, the method-specific and gender-specific
normal limits derived from relevant literature and manufacturers’ recommendations may be
used (Table 1).
Page 4 of 26
John Wiley & Sons, Inc.
Head & Neck
5
1.4 Which are the potential confounding factors in serum CT determination?
Preanalytical factors that may bias CT measurement are blood sampling from a
non-fasting subject or the recent intake of alcohol or calcium salts, possible stimulators of
CT secretion. Bacterial infections, severe disease status, hypercalcemia
(hyperparathyroidism) and renal failure may interfere as well (24). Increased CT may be
associated to several non-medullary conditions: autoimmune thyroiditis, pregnancy and
lactation, leukemia, systemic mastocytosis, small-cell lung carcinoma, breast or pancreatic
cancer (25). Hypergastrinemia and treatment with proton-pump-inhibitors for more than
two months may be associated with hypercalcitoninaema as well (26). Spurious
hypercalcitoninemia due to heterophilic antibodies (HAb) interference is also rarely
reported (20, 27, 28).
In clinical practice, due to these numerous confounding factors, a basal
hypercalcitoninaemia should always be confirmed by a second determination after the
research and exclusion of the potential interfering conditions (29). Ruled out these
circumstances, the confirmation of an elevated CT level should suggest C-cell hyperplasia
(CCH) or MTC as the most probable causes.
1.5 What basal serum CT level may be considered suspicious for MTC in clinical
practice?
Basal serum CT levels >100 pg/mL are suspicious for MTC when determined with
an IRMA or ICMA method (2,29). Serum CT elevations below this value are of difficult
interpretation (2) but their predictive value is improved by gender-specific cut-offs. In a
series of 26 histologically proved occult MTC and 74 sporadic CCH, the best PPV (88%)
was achieved by the use of a 20 pg/mL and a 80 pg/mL threshold in females and males,
respectively (30). In a prospective study, preoperatory CT levels from 20 to 100 pg/mL
resulted associated with surgical finding of CCH in 50% of cases (31).
Currently, basal CT cut-off levels are imperfect and their diagnostic accuracy should
be improved with large controlled studies. A practical approach may be based on the
results of CT levels in a multicenter consecutive series of patients with unselected thyroid
nodules (8). Serum CT levels from 20 (twice the upper reference limit) to 50 pg/mL and
from 50 to100 pg/mL demonstrated a PPV for MTC of 8% and 25%, respectively. It is
noteworthy that MTC is associated with normal serum CT levels in rare cases only (32,33).
Page 5 of 26
John Wiley & Sons, Inc.
Head & Neck
6
1.6 When should serum CT be measured?
The issue of serum CT screening for patients with thyroid nodules is partially
unsettled due to analytical problems, low prevalence of MTC, cost of routine determination
in a large population, and risk of inappropriate surgical treatment after misleading results.
The European Thyroid Association-Thyroid Cancer Network (34) and the German Society
for Endocrinology (35) recommend the use of serum CT for the screening of MTC in
patients with thyroid nodules or nodular goiter. Due to uncertainties about its cost-
effectiveness, ATA Thyroid Nodule and Cancer Guidelines recommend neither for nor
against the routine CT measurement. (2). For these reasons, the AACE/AME/ETA Thyroid
Nodule Guideline recommends the determination of serum CT in specific conditions only:
subjects with a family history of MTC or MEN, patients with indeterminate FNA cytology,
nodules with US findings suspicious for malignancy and all patients with nodular goiter
who are undergoing thyroid surgery. These recommendations limit the costs and hazards
of routine CT determination, decrease the risk of delayed diagnosis and prevent an
inadequate surgical treatment (29).
2. Stimulated serum CT
2.1 Is the diagnostic accuracy of serum CT increased by stimulation?
The available data suggest that the specificity of CT measurement is improved by
CT stimulation test (6). In Europe, a widely used method of CT stimulation was the
intravenous administration of 0.5 µg/kg of pentagastrin (PG). Serum CT was measured
before the injection, and 2 and 5 minutes thereafter (36). A clear-cut CT rise was observed
in MTC patients after the injection of PG, and a PG-stimulated CT >100 pg/mL should be
considered suspicious for CCH or MTC (2). The reported PPV of the peak of stimulated
CT is unfortunately quite variable (from 25% to 80% in different studies) (37). In large
series of unselected patients with thyroid nodules, a PG-stimulated CT >1000 pg/mL
showed a 100% PPV for MTC, whereas values between 100 and 1000 pg/mL
demonstrated a 20%PPV (8). In patients with stimulated CT values between 100 and 1000
pg/ml, the histologic finding of CCH, a premalignant proliferation or the earliest phase in
the evolution of a MTC (38), was more frequent than MTC after surgical resection (37).The
latter “false positive” diagnosis seems to involve mainly males, even if wide differences are
reported (39,30). Limits to the clinical use of CT stimulation test with PG are its difficult
Page 6 of 26
John Wiley & Sons, Inc.
Head & Neck
7
commercial accessibility, pregnancy, old age (>60 years) and concomitant cardiovascular
morbidities.
CT stimulation with the intravenous infusion of calcium gluconate (2.5 mg/Kg of
elemental calcium) has been proposed as an alternative method. This diagnostic approach
was better tolerated by patients and was at least as effective as PG test in stimulating CT
secretion in healthy subjects (40). Stimulated CT values (median and 97.5th percentile
peak values) obtained two minutes after infusion in normal subjects are 95.4 and 102
pg/mL in males and 90.2 and 78.5 pg/mL in females, respectively (40,41). Patients with
multinodular goiter (and no MTC) have peak CT levels up to 2-fold greater than controls
after calcium stimulation. In a series of 34 patients with nodular goiter and basal CT >10
pg/mL, stimulated CT levels >184 pg/mL in females and >1620 pg/mL in males provided
an accurate cut-off for the detection MTC (42). Because of the high variability of the results
from different papers, more robust data are still needed to provide a reliable diagnostic
threshold.
In clinical practice, the predictive value for MTC or CCH of an elevated basal CT is
increased by a positive stimulation test with calcium. After a stimulated CT peak >100
pg/mL the surgical option should be considered with the patient, especially if peak
values are increasing over time.
2.2 When is a stimulation test required in clinical practice?
The trigger basal CT level that suggests the use of a stimulation test varies widely
from study to study (range: 5-30 pg/mL). Basal CT concentrations tend to correlate with
the tumor mass and may be only slightly elevated in small size MTC (10). The early
identification of “micro-medullary cancers” (<10 mm) in nodular goiters with a stimulation
test may significantly decrease the number of MTC patients with extrathyroid spread at
presentation (43).
In clinical care, a stimulation test should be offered to patients with nodular goiter
and a confirmed basal CT value comprised between the upper (gender- and method-
specific) reference limit and 100 pg/mL (Table 1).
2.3 .Further CT stimulation tests
Page 7 of 26
John Wiley & Sons, Inc.
Head & Neck
8
Serum levels of CT may be stimulated by means of whisky ingestion (44) or
omeprazole treatment (45). Due to the small number of reported patients and their low
diagnostic accuracy, these tests should not be used in routine clinical care.
3. Additional serum markers for MTC
3.1 . Are there additional serum markers for the diagnosis of MTC?
Cells from MTC may produce substances such as carcinoembryonic antigen (CEA),
chromogranin A, CT-related peptide, somatostatin, adrenocorticotropic hormone, amyloid,
serotonin and vasoactive intestinal peptide. Most of these molecules are of interest only in
case of patients with advanced MTC that present syndromes like facial flushing, diarrhea
and Cushing features (1,2). Patients with poorly differentiated and more aggressive MTC
frequently show a disproportionately high CEA/CT ratio and a rapid CEA doubling time
(46). CEA may be considered as a prognostic marker during MTC follow-up and it should
be used as a complementary test in aggressive MTC type. Its baseline determination,
however, adds little to the initial diagnostic work-up in patients with thyroid nodules.
Procalcitonin (PCT), a CT precursor, was reported as an additional serum marker in the
diagnosis and follow-up of MTC (41, 47-50). An elevated PCT level may be associated
with non-MTC conditions such as systemic inflammation, infection and sepsis. The role of
PCT in detecting MTC deserves further studies, including patients with multinodular goitre
and autoimmune disease (41, 47-50).
4. Ultrasonography and other imaging techniques
4.1 Are there ultrasound risk features predictive of MTC?
US examination is the pivotal tool for the stratification of the risk of malignancy in
thyroid nodules (29). US features, such as hypoechogenicity of the lesion, presence of
irregular margins and microcalcifications, intralesional vascular signal, alone or combined,
are indicative for a malignant thyroid nodule and strongly suggest FNA biopsy (29, 51, 52).
These recommendations are mainly focused on papillary carcinoma (PTC), due to its high
prevalence (at least 80% in different series), while few contributes analyzed the US
characteristics associated with the much rarer MTC (53-58). MTC may show various
aspects at US examination. Two papers (55, 56) compared MTC and PTC sonographic
features, one studied MTC vs benign controls (54), and a last one revised a small series of
MTC with no controls (53). More recently, 12 MTC and 39 PTC cases were compared with
Page 8 of 26
John Wiley & Sons, Inc.
Head & Neck
9
a control group of benign nodules (58). On the basis of the about ninety MTC cases
reported as a whole in these small studies, traditional US risk factors for PTC seem to be
inconsistently associated with MTC. Even if the US patterns are not pathognomonic for
MTC, however, the finding of a solid and deeply hypoechoic nodule or the presence of
intralesional (especially if coarse) calcifications should suggest the possibility of a MTC
and prompt the determination of serum CT.
4.2 Are ultrasound features relevant for MTC prognosis?
As approximately 50 percent of patients have clinically detectable cervical lymph
node involvement or extracapsular diffusion at diagnosis (10), a careful sonographic
evaluation of the neck is always needed in suspicious MTC subjects. US staging may
guide the extent of surgery and help to define the preoperative patient prognosis. A study
on 77 MTC demonstrated an indolent behavior and a fairly good prognosis in 23 cancers
without US risk features, while 54 MTC with “malignant” appearance at US had a more
aggressive course (59).
4.3 Other imaging techniques
Computed tomography (CT) and magnetic resonance (MR) are useful for
preoperative staging of MTC patients with serum CT>400 pg/mL or neck ultrasound
suspicious for extracapsular spread (60). Positron emission tomography (PET) with 18F-
DOPA and 18F-FDG may be indicated during follow-up of patients with biochemical
recurrence of MTC and negative conventional imaging (61).
5. Fine needle aspiration cytology (FNA)
5.1 When should FNA be performed for the diagnosis of MTC?
Cytologic evaluation is the single most informative test for the diagnosis of thyroid
malignancy (2,29) and it should always be performed when a MTC is suspected. MTC
cytology is characterized by high cellularity with single cells or small clusters, absent
colloid and a variable amount of amiloid substance (positive at Congo-red staining)
homogeneous, in rods or spheres (38). Cytomorphology consists predominantly of round
to oval, spindle-shaped, and poligonal cells. Specimens usually present a mixture of cell
types and are characterized by dispersed pattern with loosely cohesive groups.
Pseudofollicular arrangement may rarely be seen but follicles or papillary structures are
not identified (62,63). The cytoplasm is slightly granular, and is usually configured as a
Page 9 of 26
John Wiley & Sons, Inc.
Head & Neck
1
tear drop or cytoplasmic tail. Azurophilic cytoplasmic granules may be seen in air-dried
smears. Nuclei are located eccentrically and are more large and pleomorphic than those of
follicular cells (64,65). Bi- and multinucleation occur frequently, while the presence of
nucleoli is not a consistent finding (62). A reliable confirmation of the cytologic diagnosis is
obtained by immunocytochemistry with antibodies directed against CT. Positive reactivity
of CT on cytologic smears was reported to correlate with MTC histology in 100% of cases
(66,62). Immunocytochemical staining, however, may be difficult in samples with a poor
cellularity. In these cases an US-guided core-needle thyroid biopsy may be useful (67).
5.2 Is thyroid cytology accurate for MTC?
Due to the dispersed pattern with pleomorphism, diagnostic surgery is frequently
recommended even if a conclusive diagnosis is not made on FNA. (65). A few papers
have analyzed the diagnostic accuracy of cytology in detecting MTC. FNA sensitivity for
MTC is lower than for differentiated or anaplastic thyroid cancer (6,7). In a series of 44
cases, serum CT determination had higher sensitivity with respect to cytology (6). Only 20
nodules resulted cytologically suspicious for MTC (45% sensitivity), while 9 (20%) were
reported as “undefined malignancy”. In a retrospective study on 77 MTC, FNA sensitivity
was 63% while serum CT showed a sensitivity of 98%. Moreover, FNA was able to detect
only 74.5% of MTC suspected on the basis of an elevated serum CT (7). It is of note that
in both papers a non-negligible part of MTC was read as benign (up to 25% of MTC) or
non conclusive (up to 9%) (6,7). Unpublished data of the Authors of this review
display a 18% of histologically proved MTC having a benign and a 23% having a non
conclusive cytologic report. With a different study design, Papaparaskeva et al (68) and
Forrest et al (69) reviewed the aspirates reading of MTC and reported that this cancer was
histologically confirmed in 81/91 (89% PPV) and 17/21 (81% PPV) cytologies,
respectively. The need for surgery was, anyway, indicated in 99% of cases. A recent
study confirmed a trend toward a better diagnostic accuracy for MTC of thyroid cytology. In
a series of rare thyroid malignancies, it was reported a 83% sensitivity and a 100%
predictive value for MTC using the Bethesda reporting system for thyroid cytology (70).
Based on the above papers (6,7,68-70), MTC may have a non conclusive
report at FNA cytology. In clinical practice, the determination of serum CT in
patients with nodules cytologically read as indeterminate should always be
performed to exclude MTC.
Page 10 of 26
John Wiley & Sons, Inc.
Head & Neck
1
6. CT measurement in FNA washout (FNA-CT)
6.1 What is the rationale for FNA-CT?
C cells produce CT and the measurement of CT in needle washout after biopsy is
helpful in localizing MTC. The few papers that evaluated the role of FNA-CT for the
diagnosis of MTC consistently showed that FNA-CT has a high accuracy (71-76).
6.2 When is the determination of FNA-CT indicated?
When a thyroid lesion is suspicious for MTC, FNA-CT should always be determined
to prevent the risk of false negative cytologic reports. In multinodular goiters, FNA-CT may
localize the MTC lesion and allows a better planning of the surgical approach. All patients
with an elevated serum CT who undergo biopsy should perform a FNA-CT determination.
6.3 How to prepare and determine FNA-CT?
To date, there is no established method for FNA-CT sampling. Papers on FNA-CT
used different assays and various modalities of preparation of the sample (e.g. washout in
1 ml of saline solution or analytical buffer) (71-76). This heterogeneous approach may lead
to some discrepancy in the results. A recent paper (77) compared the use of saline
solution and of specific CT-free buffer in patients without C cells disease. The results
showed no significant difference between the two methods.
6.4 Is there an established cut-off level for FNA-CT?
Currently, there is no established cut-off of FNA-CT for the diagnosis of MTC.
Arbitrary cut-off levels based on small series of patients were proposed by some authors
at 36 pg/mL (71) or over 67 pg/ml (72). One paper reported that non-medullary nodules
may have CT levels on FNA washout up to 8.5 pg/ml (77). It is noteworthy that MTC
associated with a low FNA-CT value have never been reported.
7. RET (REarranged during Transfection) Mutations
7.1 Which is the clinical role of the genetic screening for RET?
Germline testing makes possible to differentiate hereditary from sporadic MTC cases. Up
to 7% of patient with apparent sporadic MTC carry a germline RET mutation, and 2-9% of
these are de novo ones (78-80). When the familial nature of MTC is assessed in the
proband, RET genetic screening of the relatives reliably recognizes the asymptomatic
Page 11 of 26
John Wiley & Sons, Inc.
Head & Neck
1
gene carriers of the identified RET mutation. In a recent report, a germline RET mutation
was discovered in 6.5% of apparently sporadic MTC, and 58.2% of the relatives who
resulted gene carriers had biochemical or clinical evidence of MTC (81). The identification
of a specific RET mutation makes possible:
- to stratify patients into different categories for the risk of aggressive MTC
- to establish the indication and the timing for the screening of pheochromocytoma
and hyperparathyroidism
- to select the timing for genetic screening of the relatives and for prophylactic
thyroidectomy in those who result RET mutation carriers
- to reassure the relatives who do not carry RET mutations.
7.2 Which RET mutations should be investigated?
Over 98% of MEN 2A, 95% of MEN 2B and 85% of FMTC patients carry an
identifiable germline RET mutation (82-84). RET mutations of MEN 2A and FMTC are
more commonly located in exon 10 (codons 609, 611, 618, 620, 630) and exon 11 (codon
634). The latter is the most common, accounting for 80-85% of MEN 2A and 25-30% of
FMTC (85). About 95% of MEN 2B patients carry mutation in codon 918 of exon 16, while
the remaining 5% have codon 883 mutation or two-hit mutations of 804 codon with 805,
806 or 904.
In clinical practice a multiple-step approach should be followed (2). Testing of RET
mutation should first include exons 10 and 11 and 13 through 16 (86). If genetic test
results are negative, exons 5 and 8 should be examined as well (1).
7.3 When RET oncogene germinal mutation should be researched?
RET sequencing is needed in all cases of MTC. Even in the absence of family
history of MTC, germline RET testing should be offered to:
- all patients with a personal history of primary CCH, MTC, or MEN2;
- all subjects with a family history of MEN2 or FMTC. In MEN2B the genetic screening
should be done shortly after birth and in MEN2A and in FMTC before five years of age;
- patients with intestinal ganglioneuromatosis or lichen planus amyloidosis in the central
upper area of their back as they are at risk to be a variant of MEN2A or FMTC with a
634 codon mutation (2).
Page 12 of 26
John Wiley & Sons, Inc.
Head & Neck
1
Genetic analysis should be performed in all first-degree relatives of a MTC patient
with an identified germline RET mutation. The potential gene carriers of the family
should be tested before the recommended age of prophylactic thyroidectomy (2).
Hirschsprung disease cosegregates with a few RET mutations for MEN2A/FMTC, even
if at a low penetrance. In these cases the genetic screening should be directed to exon
10, codons 609, 611, 618, 620 (87).
7.4 Which role the RET genotype-phenotype correlation plays in MEN2
management?
A tight correlation is present between specific germline RET mutations, the age of
onset of MTC and its aggressiveness (88,89). RET mutations may be stratified in 4 levels
of risk for aggressive behaviour (2):
- Level D: highest risk for aggressive MTC (i.e. codons 918, 883, MEN2B). RET testing,
thyroid ultrasound, serum CT determination, and prophylactic thyroidectomy are
indicated as soon as possible, preferably within the first year after birth;
- Level C (codon 634, MEN2A): high risk for aggressive MTC. Children should undergo
prophylactic thyroidectomy before the age of 5 years;
- Level B (codons 609, 611, 618, 620, 630): low risk for aggressive MTC:
- Level A (codons 768, 790, 791, 804, 891): least risk.
The recommended age for RET testing for levels C, B and A is before 3-5 years. The
recommended age for initial thyroid US examination and the determination of serum CT is
>3-5 years (Table 2). It has been suggested that in level A, B and C carriers of the RET
gene, due to the heterogeneous phenotype and the risk of surgical complications in early
childhood, serum levels of basal and stimulated CT should be used to personalize the
timing of surgery. Thyroidectomy could be performed when stimulated CT becomes
positive, independently of the type of RET mutation and the patient’s age. This approach
was reported to offer a similar outcome when compared with the traditional timing of
prophylactic thyroidectomy (90,91). Caution, however, is appropriate for level-C RET
mutation gene carries and more data are needed to confirm this management approach.
7.5 What is the prognostic significance of the somatic mutations of RET
oncogene in sporadic MTC?
Approximately 60 % percent of sporadic MTC have somatic mutations in their RET
gene that are present in the tumor cells only and are undetectable by genetic testing on
Page 13 of 26
John Wiley & Sons, Inc.
Head & Neck
1
leukocyte DNA. Somatic RET mutations occur at several codons (608, 618, 629, 630, 634,
649, 641, 918, 922) and most frequently at codon 918 (79,92-95). The presence of
somatic RET mutations was correlated with a worse outcome of patients, as showed by a
highest rate of cancer persistence and a lower survival rate (96). Somatic 918 mutation
was associated with a more aggressive MTC behavior (97,98) and mutations in exons 15
and 16 of the RET gene are reported to correlate with lymph node metastases, persistent
disease, and lower survival. In sporadic MTC patients who are positive for somatic RET
mutation a close follow-up is appropriate. Somatic (acquired) RET mutations are still of
uncertain prognostic significance and their routine research on tumor tissue is not
suggested in clinical practice (1).
8. When coexisting tumors should be researched?
Patients with unknown mutational status or who have established germline RET
mutations should be always tested for pheocromocytoma and hyperparathyroidism prior to
thyroidectomy. In sporadic MTC patients who are negative for RET germline mutation,
biochemical testing for coexisting tumors is not necessary (1).
Conclusions for a diagnostic approach in clinical practice
MTC is a potentially lethal tumor and its cure is strongly dependent by a well-timed
diagnosis and appropriate treatment. Hence, a careful use and correct interpretation of the
existing diagnostic tools are needed. Serum CT measurement represents the most
sensitive test for an early diagnosis of MTC. Serum CT should always be tested in
subjects with a family history positive for MTC, CCH, or MEN2. Thyroid US scan is a
relevant diagnostic tool for differentiated thyroid carcinoma but is less predictive for MTC.
Due to the imperfect diagnostic accuracy of US examination and the possible false-
negative results of cytology by FNA, serum CT determination is suggested in patients with
thyroid nodule features that warrant FNA biopsy, with an “indeterminate” cytologic report or
who are undergoing thyroid surgery for any reason. For the same reasons, in patients
undergoing nodule aspiration following the finding of an elevated serum CT, the CT
determination in needle washout fluid should be performed. Elevated values of FNA-CT
should be considered strongly indicative for MTC and prompt surgery. RET sequencing is
mandatory in patients with MTC (even if apparently sporadic), CCH, or MEN2 and in all
first-degree relatives of an MTC patient after the demonstration of a germline RET
Page 14 of 26
John Wiley & Sons, Inc.
Head & Neck
1
mutation. In absence of a known mutation, a multiple-step approach should be followed for
genetic testing.
Page 15 of 26
John Wiley & Sons, Inc.
Head & Neck
1
Tables
Table 1. Method-specific and gender-specific normal CT references for different
assays.
Assay Manufacturer Method LoD LoQ Reference Range [pg/mL]
Elsa-hCT Cis Bio IRMA 1.5 5.5 m/f <10
m <9.54, f <8.25
Immulite
2000 DPC ICMA 2 5
m <16, f <8
m <8.4, f <5
Liaison II DIASORIN ICMA 1 3 m <21.9, f <11.1
m <18.9, f <5.5
Selco-CT MEDIPAN IRMA 1.6 - m <15, f <10
Table 2. RET genotype-phenotype correlation and MEN 2 management. Modified from Kloos (2).
Codon 515, 531, 600,
603, 777, 912
533, 649, 666,
768, 790, 791,
804, 891
609, 611, 618,
620, 630, 631,
633
634 883, 918,
804+778,
804+805,
804+806,
804+904
ATA risk level A A B C D
MEN 2 FMTC FMTC/MEN 2A MEN 2A MEN 2° MEN 2B
Age of RET
testing
Before 3-5 years Before 3-5
years
Before 3-5
years
Before 1 year
Age of first
serum CT
>3-5 years >3-5 years >3-5 years Before 1 year
Age of first
thyroid US
>3-5 years >3-5 years >3-5 years Before 1 year
Age of
prophylactic
surgery
Surgery may be delayed> 5 years
if annual basal and stimulated CT,
and annual US are normal
Surgery may be
delayed> 5
years if annual
basal and
stimulated CT,
and annual US
are normal
5 years Before 1 year
Page 16 of 26
John Wiley & Sons, Inc.
Head & Neck
1
References
1. Tuttle Michael. Medullary thyroid cancer: clinical manifestations, diagnosis and
staging. In: UptoDate www.uptodate.com. Wolters Kluwer; 2012
2. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, et
al. Medullary thyroid cancer: management guidelines of the American Thyroid
Association. Thyroid 2009; 19:565-612.
3. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid
carcinoma: clinical characteristics, treatment, prognostic factors and a comparison of
staging systems. Cancer 2000; 88:1139-1148.
4. Williams GA, Hargis GK, Galloway WB, Henderson WJ. Evidence for thyrocalcitonin in
man Proc Soc Exp Biol Med 1966; 122:1273-1276.
5. Horn RC, Ravdin IS. Carcinoma of the thyroid gland in youth. J Clin Endocrinol Metab.
1951; 11:1166-1178.
6. Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin
on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864
patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004; 89:163-168.
7. Bugalho MJM, Santos JR, Sobrinho L. Preoperative diagnosis of medullary thyroid
carcinoma: fine needle aspiration cytology as compared with serum calcitonin
measurement. J Surg Oncol 2005; 91:56-60.
8. Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels
for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817
consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007; 92:450-455.
9. Cheung K, Roman SA, Wang TS, Walker HD, Sosa JA. Calcitonin measurement in the
evaluation of thyroid nodules in the United States: a cost-effectiveness and decision
analysis. J Clin Endocrinol Metab 2008; 93:2173-180.
10. Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary thyroid carcinoma. Clin
Oncol (R Coll Radiol) 2010; 22: 475-485.
11. Tuttle RM, Ball DW, Byrd D, et al. Medullary carcinoma. J Natl Compr Canc Netw
2010; 8:512-530.
Page 17 of 26
John Wiley & Sons, Inc.
Head & Neck
1
12. Saller B, Görges R, Reinhardt W, Haupt K, Janssen OE, Mann K. Sensitive calcitonin
measurement by two-site immunometric assays: implications for calcitonin screening
in nodular thyroid disease. Clin Lab 2002; 48:191-200
13. Leboeuf R, Langlois MF, Martin M, Ahnadi CE, Fink GD. "Hook effect" in calcitonin
immunoradiometric assay in patients with metastatic medullary thyroid carcinoma:
case report and review of the literature. J Clin Endocrinol Metab. 2006; 91:361-364
14. Perdrisot R, Bigorgne JC, Guilloteau D, Jallet P. Monoclonal immunoradiometric assay
of calcitonin improves investigation of familial medullary thyroid carcinoma. Clin Chem
1990; 36: 381-383.
15. Zink A, Blind E, Raue F. Determination of serum calcitonin by immunoradiometric two-
site assays in normal subjects and patients with medullary thyroid carcinoma. Eur J
Clin Chem Clin Biochem 1992; 30: 831-835.
16. Grauer R, Raue F, Ziegler R. Clinical usefulness of a new chemiluminescent two-site
immunoassay for human calcitonin. Exp Clin Endocrinol Diabetes 1998; 106:353-359.
17. Bieglmayer C, Vierhapper H, Dudczack R, Niederle B. Measurement of calcitonin by
immunoassay analyzers. Clin Chem Lab Med 2007; 45: 662-666.
18. Barbot N, Calmettes C, Schuffenecker I, et al. Pentagastrin stimulation test and early
diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of
calcitonin: comparison with genetic screening in hereditary medullary thyroid
carcinoma. J Clin Endocrinol Metab 1994; 78:114-120.
19. Karges W, Dralle HH, Raue F, et al. German Society for Endocrinology (DGE): Thyroid
Section. Calcitonin measurement to detect medullary thyroid carcinoma in nodular
goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol
Diabetes 2004; 112:525-528.
20. D’Herbomez M, Caron P, Bauters C, et al. Reference range of serum calcitonin levels
in humans: influence of calcitonin assays, sex, age, and cigarette smoking. Eur J
Endocrinol 2007; 157:749-755.
21. Ramachandran R, Benfield P, Dhillo WS, et al. Need for revision of diagnostic limits for
medullary thyroid carcinoma with a new immunochemiluminometric calcitonin assay.
Clin Chem 2009; 55:2225-2226.
Page 18 of 26
John Wiley & Sons, Inc.
Head & Neck
1
22. Guyetant S, Rousselet MC, Durigon M, et al. Sex-related C cell hyperplasia in the
normal human thyroid: a quantitative autopsy study. J Clin Endocrinol Metab 1997; 82:
42-47.
23. Giovanella L, Imperiali M, Ferrari A, et al. Thyroid volume influences serum calcitonin
levels in a thyroid-healthy population: a 3-assays, 519 subject study. Clin Chem Lab
Med 2012; 50:895-900
24. Toledo SP, Lourenço DM Jr, Santos MA, Tavares MR, Toledo RA, Correia-Deur JE.
Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics
(Sao Paulo) 2009; 64:699-706.
25. Castro MR, Gharib H. Continuing controversies in the management of thyroid nodules.
Ann Intern Med 2005; 142: 926-931.
26. Erdogan MF, Gursoy A, Kulaksizoglu M. Long-term effects of elevated gastrin levels
on calcitonin secretion. J Endocrinol Invest 2006; 29:771-775.
27. Vantyghem MC, Danel T, Marcelli-Tourvielle S, et al. Calcitonin levels do not decrease
with weaning in chronic alcohlism. Thyroid 2007; 17: 213-217.
28. Giovanella L, Suriano S. Spurious hypercalcitoninemia and heterophilic antibodies in
patients with thyroid nodules. Head & Neck 2010; 33:95-97.
29. Gharib H, Papini E, Paschke R, et al. AACE/AME/ETA Task Force on Thyroid
Nodules.. American Association of Clinical Endocrinologists, Associazione Medici
Endocrinologi, and European Thyroid Association medical guidelines for clinical
practice for the diagnosis and management of thyroid nodules. J Endocrinol Invest
2010; 33:1-50.
30. Machens A, Hoffmann F, Sekulla C, Dralle H. Importance of gender-specific calcitonin
thresholds in screening for occult sporadic medullary thyroid cancer. Endocr Relat
Cancer 2009; 16:1291-1298.
31. Ahmed SR, Ball DW. Incidentally discovered medullary thyroid cancer: diagnostic
strategies and treatment. J Clin Endocrinol Metab 2011; 96:1237-1245.
Page 19 of 26
John Wiley & Sons, Inc.
Head & Neck
2
32. Dora JM, Canalli MH, Capp C, Punales MK, Vieira JJG, Maia AL. Normal perioperative
serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case
report and review of the literature. Thyroid 2008; 18:895-899.
33. Giovanella L, Crippa S, Ceriani L. Serum calcitonin-negative medullary thyroid
carcinoma: role of CgA and CEA as complementary markers. Int J Biol Markers 2008;
23:129-131.
34. Schlumberger M, Bastholt L, Dralle H, Jarzab B, Pacini F, Smit JWA. The European
Thyroid Association Task Force 2012 European Thyroid Association Guidelines for
Metastatic Medullary Thyroid Cancer. Eur Thyroid J 2012; 1:5–14
35. Karges W, Dralle H, Raue F, et al. German Society for Endocrinology (DGE) - Thyroid
Section. Calcitonin measurement to detect medullary thyroid carcinoma in nodular
goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol
Diabetes 2004; 112:52-58.
36. Wells SA Jr, Baylin SB, Linehan WM, Farrell RE, Cox EB, Cooper CW. Provocative
agents and the diagnosis of medullary thyroid carcinoma of the thyroid gland. Ann
Surg 1978; 188: 139-141.
37. Costante G, Durante C, Francis Z, Schlumberger M, Filetti S. Determination of
calcitonin in C-cell disease: clinical interest and potential pitfalls. Nat Clin Pract
Endocrinol Metab 2009; 5:35-44.
38. Wenig BM, Heffness CS, Adair CF. Atlas of endocrine pathology. Philadelphia, WB
Saunders Company. 1997. 374 p.
39. Vierhapper H, Niederle B, Bieglmayer C, Kaserer K, Baumgartner-Parzer S. Early
diagnosis and curative therapy of medullary thyroid carcinoma by routine
measurement of serum calcitonin in patients with thyroid disorders. Thyroid 2005; 15:
1267-1272
40. Doyle P, Dueren C, Nerlich K, et al. Potency and tolerance of calcitonin stimulation
with high-dose calcium versus pentagastrin in normal adults. J Clin Endocrinol Metab
2009; 94: 2970-2974.
41. Giovanella L. Serum Procalcitonin and Calcitonin Normal Values Before and After
Calcium Gluconate Infusion. Exp Clin Endocrinol Diabet 2012; 120:169-170.
Page 20 of 26
John Wiley & Sons, Inc.
Head & Neck
2
42. Colombo C, Verga U, Mian C, et al. Comparison of calcium and pentagastrin tests for
the diagnosis and follow-up of medullary thyroid carcinoma. J Clin Endocrinol Metab
2012; 97:905-913.
43. Scheuba C, Kaserer K, Bieglmayer C. Medullary thyroid microcarcinoma
recommendations for treatment - a single-center experience. Surgery 2007; 142:1003-
1010.
44. Emmertsen KK, Nielsen HE, Mosekilde L, Hansen HH. Pentagastrin, calcium and
whisky stimulated serum calcitonin in medullary carcinoma of the thyroid. Acta Radiol
Oncol 1980, 19: 85-89.
45. Vitale G, Ciccarelli A, Caraglia M, et al. Clin Chem 2002; 48:1505-1510.
46. Machens A, Ukkat J, Hauptmann S, Dralle H. Abnormal carcinoembryonic antigen
levels and medullary thyroid cancer progression: a multivariate analysis. Arch Surg
2007; 142:289-293.
47. Algeciras-Schimnich A, Preissenr CM, Theobald P, Finseth MS, Grebe SK.
Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary
thyroid carcinoma. J Clin Endocrinol Metab 2009; 94:861–868.
48. Giovanella L, Maffioli M, Suriano S, Dorizzi RM. Elevated calcitonin and procalcitonin
levels in nonmedullary benign and malignant thyroid nodules. Clin Endocrinol 2010;
72: 852-853.
49. Kratzsch J, Petzold A, Raue F, at al. Basal and stimulated calcitonin and procalcitonin
in various assays in patients with and without medullary thyroid cancer. Clin Chem
2011; 57:467-474.
50. Giovanella L, Verburg FA, Imperiali M, Valabrega S, Trimboli P, Ceriani L. Comparison
of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among
patients with thyroid nodules. Clin Chem Lab Med. 2012 Dec 25:1-5.
doi:10.1515/cclm-2012-0610.
51. Rago T, Vitti P, Chiovato L, et al. Role of conventional ultrasonography and color flow-
doppler sonography in predicting malignancy in cold thyroid nodules. Eur J Endocrinol
1998; 138:41-46.
Page 21 of 26
John Wiley & Sons, Inc.
Head & Neck
2
52. Papini E, Guglielmi R, Bianchini A, et al. (2002) Risk of malignancy in nonpalpable
thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin
Endocrinol Metab 2002; 87:1941-1946.
53. Gorman B, Charboneau JW, James EM, et al. Medullary thyroid carcinoma: role of
high-resolution US. Radiology 1987; 162:147-150.
54. Saller B, Moeller L, Gorges R, Janssen OE, Mann K. Role of conventional ultrasound
and color Doppler sonography in the diagnosis of medullary thyroid carcinoma. Exp
Clin Endocrinol Diabetes 2002; 110:403-407.
55. Kim SH, Kim BS, Jung SL, et al. Ultrasonographic findings of medullary thyroid
carcinoma: a comparison with papillary thyroid carcinoma. Korean J Radiol
2009;10:101-105.
56. Lee S, Shin JH, Han BK, Ko EY. Medullary thyroid carcinoma: comparison with
papillary thyroid carcinoma and application of current sonographic criteria. Am J
Roentgenol 2010; 194:1090-1094.
57. Choi N, Moon WJ, Lee JH, et al. Ultrasonographic findings of medullary thyroid
cancer: differences according to tumor size and correlation with fine needle aspiration
results. Acta Radiol 2011; 52:312-316.
58. Trimboli P, Nasrollah N, Amendola S, et al. Should we use ultrasound features
associated with papillary thyroid cancer in diagnosing medullary thyroid cancer?
Endocr J 2012; 59:503-508.
59. Fukushima M, Ito Y, Hirokawa M, et al. Excellent prognosis of patients with
nonhereditary medullary thyroid carcinoma with ultrasonographic findings of follicular
tumor or benign nodule. World J Surg 2009; 33:963-968.
60. Seo YL, Yoon DY, Baek S, et al. Detection of neck recurrence in patients with
differentiated thyroid cancer: comparison of ultrasound, contrast-enhanced CT and
(18)F-FDG PET/CT using surgical pathology as a reference standard: (ultrasound vs.
CT vs. (18)F-FDG PET/CT in recurrent thyroid cancer). Eur Radiol 2012; 22:2246-
2254
Page 22 of 26
John Wiley & Sons, Inc.
Head & Neck
2
61. Kauhanen S, Schalin-Jäntti C, Seppänen M, et al. Complementary roles of 18F-DOPA
PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J Nucl Med 2011;
52:1855-1863
62. Kini SR. Thyroid Cytopathology. An atlas and text. Philadelphia: Lippincott Williams &
Wilkins 2008. 550 p.
63. DeLellis RA, Lloyd RV, Heitz PU, Eng C. WHO Classification of tumours. Pathology
and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press 2004,
64. Bhanot P, Yang J, Schnadig VJ, Logroño R. Role of FNA cytology and
immunochemistry in the diagnosis and management of medullary thyroid carcinoma:
report of six cases and review of the literature. Diagn Cytopathol. 2007; 35:285-292.
65. Ross DS. Atlas of thyroid Cytopathology. UptoDate www.uptodate.com. Wolters
Kluwer 2012.
66. De May RM. The art and science of cytopathology, Aspiration cytology. Chicago:
ASCP Press. 1996. 703 p.
67. Park, K.T., Ahn, S.H., Mo, J, et al. Role of core needle biopsy and ultrasonographic
finding in management of indeterminate thyroid nodules. Head Neck 2011; 33:160-
165.
68. Papaparaskeva K, Nagel H, Droese M. Cytologic diagnosis of medullary carcinoma of
the thyroid gland. Diagn Cytopathol 2000; 22:351-358.
69. Forrest CH, Frost FA, de Boer WB, Spagnolo DV, Whitaker D, Sterrett BF. Medullary
carcinoma of the thyroid: accuracy of diagnosis of fine-needle aspiration cytology.
Cancer 1988; 84: 295-302.
70. Dustin SM, Jo VY, Hanley KZ, Stelow EB. High sensitivity and positive predictive value
of fine-needle aspiration for uncommon thyroid malignancies. Diagn Cytopathol 2012;
40:416-421.
71. Boi F, Maurelli I, Pinna G, et al. Calcitonin measurement in washout fluid from fine
needle aspiration of neck masses in patients with primary and metastatic medullary
thyroid carcinoma. J Clin Endocrinol Metab 2007; 92:2115-2118.
Page 23 of 26
John Wiley & Sons, Inc.
Head & Neck
2
72. Kudo T, Miyauchi A, Ito Y, Takamura Y, Amino N, Hirokawa M. Diagnosis of medullary
thyroid carcinoma by calcitonin measurement in fine needle aspiration biopsy
specimens. Thyroid 2007;17:635-638.
73. Massaro F, Dolcino M, Degrandi R, et al. Calcitonin assay in wash-out fluid after fine-
needle aspiration biopsy in patients with a thyroid nodule and border-line value of the
hormone. J Endocrinol Invest 2009; 32:308-312.
74. Abraham D, Gault PM, Hunt J, Bentz J. Calcitonin estimation in neck lymph node fine-
needle aspirate fluid prevents misinterpretation of cytology in patients with metastatic
medullary thyroid cancer. Thyroid 2009; 19:1015-1016.
75. Trimboli P, Rossi F, Baldelli R, et al. Measuring calcitonin in washout of the needle in
patients undergoing fine needle aspiration with suspicious medullary thyroid cancer.
Diagn Cytopathol 2012; 40:394-8.
76. Trimboli P, Nigri G, Romanelli F, et al. Medullary thyroid nodules by measurement of
calcitonin (Ct) in aspiration needle washout in patients with multinodular goiter and
moderately elevated serum Ct. Exp Clin Endocrinol Diabetes 2012; 120:234-237.
77. Giovanella L, Ceriani L, Bongiovanni M. Calcitonin measurement on fine needle
washouts: Preanalytical Issues and Normal Reference Values. Diagn Cytopathol. 2011
Dec 5. doi: 10.1002/dc.22804.
78. Eng C, Mulligan LM, Smith DP, et al. Low frequency of germline mutations in the RET
proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin
Endocrinol 1995; 43:123-127
79. Wohllk N, Cote GJ, Bugalho MM, et al. Relevance of RET proto-oncogene mutations
in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1996;81:3740-3745
80. Schuffenecker I, Ginet N, Goldgar D, et al. Prevalence and parental origin of de novo
RET mutations in multiple endocrine neoplasia type 2 and familial medullary thyroid
carcinoma. Le Groupe d’Etude des Tumeurs a Calcitonine. Am J Hum Genet
1997;60:233-237.
81. Romei C, Cosci B, Renzini G, et al. RET genetic screening of sporadic medullary
thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers
Page 24 of 26
John Wiley & Sons, Inc.
Head & Neck
2
and the identification of a relevant percentage of hidden familial MTC (FMTC). Clin
Endocrinol 2011;74:241-247.
82. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-
oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363:458-460.
83. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are
associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-856.
84. Eng C, Smith DP, Mulligan LM, et al. Point mutation within the tyrosine kinase domain
of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related
sporadic tumours. Hum Mol Genet 1994; 3:237-241.
85. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-
oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2.
International RET mutations consortium analysis. JAMA 1996; 276:1575-1579.
86. Moline J, Eng C. Multiple endocrine neoplasia type 2: an overview. Genet Med 2011;
13:755-764.
87. Mullingan LM, Eng C, Attiè T et al. Diverse phenotypes associated with exon 10
mutations of the RET proto-oncogene. Hum Mol Genet 1994; 3:2163-2167.
88. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary
medullary thyroid cancer. N Engl J Med 2003; 349:1517-1525
89. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN
type Iand type 2. J Clin Endocrinol Metab 2001; 86:5658-5671.
90. Rohmer V, Vidal-Trecan G, Bourdelot A, et al. Prognostic factors of disease-free
survival after thyroidectomy in 170 young patients with a RET germline mutation: a
multicenter study of the Groupe Franḉais d’Etude des Tumeurs Endocrines. J Clin
Endocrinol Metab 2011; 96:E509-E518.
91. Elisei R, Romei C, Renzini G, et al. The timing of total thyroidectomy in RET gene
mutation carriers could be personalized and safely planned on the basis of serum
calcitonin: 18 years experience at one single center. J Clin Endocrinol Metab 2012;
97:426-435.
Page 25 of 26
John Wiley & Sons, Inc.
Head & Neck
2
92. Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene
associated with multiple endocrine neoplasia type 2B and sporadic medullary
carcinoma. Nature 1994; 367:375-376
93. Marsh DJ, Learoyd DL, Andrew SD, et al. Somatic mutations in the RET proto-
oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol 1996; 44:249-257
94. Romei C, Elisei R, Pinchera A, et al. Somatic mutations of the RET protooncogene in
sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated
with tumor recurrence. J Clin Endocrinol Metab 1996; 81:1619-1622
95. de Groot JW, Links TP, Plukker JT, et al. RET as a diagnostic and therapeutic target in
sporadic and hereditary endocrine tumors. Endocr Rev 2006;27:535-560
96. Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene
mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin
Endocrinol Metab 2008; 93:682-687
97. Zedenius J, Larsoon C, Bergholm U, et al. Mutations of codon 918 in the RET proto-
oncogene to poor prognosis in sporadic medullary thyroid carcinoma. J Clin Endocrinol
Metab 1995; 80:3088-3090
98. Schilling T, Burck J, Sinn HP, et al. Prognostic value of codon 918 (ATG-AGC) RET
proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 2001;
95:62-66.
Page 26 of 26
John Wiley & Sons, Inc.
Head & Neck